Revolution Medicines, Inc. - Common Stock (RVMD)
CUSIP: 76155X100
Q2 2024 13F Holders as of 30 Jun 2024
- Type / Class
- Equity / Common Stock
- Shares outstanding
- 192,966,469
- Total 13F shares
- 168,410,110
- Share change
- +7,776,055
- Total reported value
- $6,536,274,916
- Put/Call ratio
- 53%
- Price per share
- $38.81
- Number of holders
- 221
- Value change
- +$309,463,084
- Number of buys
- 119
- Number of sells
- 84
Quarterly Holders Quick Answers
What is CUSIP 76155X100?
CUSIP 76155X100 identifies RVMD - Revolution Medicines, Inc. - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 76155X100:
Top shareholders of RVMD - Revolution Medicines, Inc. - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| VANGUARD GROUP INC |
13F
|
Company |
7.6%
|
14,757,112
|
$475,621,720 | — | 31 Mar 2024 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
7.6%
|
14,714,726
|
$474,255,619 | — | 31 Mar 2024 | |
| BlackRock Finance, Inc. |
13F
|
Company |
6.4%
|
12,308,002
|
$396,686,904 | — | 31 Mar 2024 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
3.9%
|
7,549,249
|
$243,312,295 | — | 31 Mar 2024 | |
| FARALLON CAPITAL MANAGEMENT LLC |
13F
|
Company |
—
mixed-class rows
|
7,627,957
mixed-class rows
|
$241,997,929 | — | 31 Mar 2024 | |
| Nextech Invest Ltd. |
13F
|
Company |
3.3%
|
6,296,740
|
$202,943,930 | — | 31 Mar 2024 | |
| BVF INC/IL |
13F
|
Company |
3.1%
|
5,981,212
|
$192,774,463 | — | 31 Mar 2024 | |
| Casdin Capital, LLC |
13F
|
Company |
2.9%
|
5,617,599
|
$181,055,216 | — | 31 Mar 2024 | |
| STATE STREET CORP |
13F
|
Company |
2.8%
|
5,386,020
|
$173,591,425 | — | 31 Mar 2024 | |
| Alphabet Inc. |
13F
|
Company |
2.7%
|
5,301,512
|
$170,867,731 | — | 31 Mar 2024 | |
| Bellevue Group AG |
13F
|
Company |
2.6%
|
5,073,600
|
$163,522,128 | — | 31 Mar 2024 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
—
mixed-class rows
|
5,421,746
mixed-class rows
|
$155,264,000 | — | 31 Mar 2024 | |
| Boxer Capital, LLC |
13F
|
Company |
2.2%
|
4,279,464
|
$137,927,125 | — | 31 Mar 2024 | |
| Third Rock Ventures III, L.P. |
3/4/5
|
10%+ Owner |
—
class O/S missing
|
5,104,130
|
$137,811,510 | — | 08 Jun 2022 | |
| FMR LLC |
13F
|
Company |
2.2%
|
4,166,765
|
$134,294,836 | — | 31 Mar 2024 | |
| JANUS HENDERSON GROUP PLC |
13F
|
Company |
2%
|
3,912,119
|
$126,066,596 | — | 31 Mar 2024 | |
| Woodline Partners LP |
13F
|
Company |
2%
|
3,797,148
|
$122,382,080 | — | 31 Mar 2024 | |
| JPMORGAN CHASE & CO |
13F
|
Company |
1.8%
|
3,509,104
|
$113,098,422 | — | 31 Mar 2024 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.6%
|
3,090,073
|
$99,593,053 | — | 31 Mar 2024 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
3,052,691
|
$98,402,137 | — | 31 Mar 2024 | |
| Paradigm Biocapital Advisors LP |
13F
|
Company |
1.5%
|
2,914,975
|
$93,949,644 | — | 31 Mar 2024 | |
| a16z Capital Management, L.L.C. |
13F
|
Company |
1.4%
|
2,748,523
|
$88,584,896 | — | 31 Mar 2024 | |
| Holocene Advisors, LP |
13F
|
Company |
1.3%
|
2,422,411
|
$78,074,307 | — | 31 Mar 2024 | |
| NORGES BANK |
13F
|
Company |
0.89%
|
1,708,276
|
$55,057,735 | — | 31 Mar 2024 | |
| AMERIPRISE FINANCIAL INC |
13F
|
Company |
0.88%
|
1,694,501
|
$54,613,758 | — | 31 Mar 2024 | |
| BALYASNY ASSET MANAGEMENT L.P. |
13F
|
Company |
0.86%
|
1,654,895
|
$53,337,266 | — | 31 Mar 2024 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.8%
|
1,535,940
|
$49,503,346 | — | 31 Mar 2024 | |
| DIMENSIONAL FUND ADVISORS LP |
13F
|
Company |
0.69%
|
1,331,259
|
$42,906,477 | — | 31 Mar 2024 | |
| Artal Group S.A. |
13F
|
Company |
0.68%
|
1,318,649
|
$42,500,057 | — | 31 Mar 2024 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.63%
|
1,214,271
|
$39,135,955 | — | 31 Mar 2024 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
0.58%
|
1,123,450
|
$36,208,794 | — | 31 Mar 2024 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.55%
|
1,052,263
|
$33,914,436 | — | 31 Mar 2024 | |
| Frazier Life Sciences Management, L.P. |
13F
|
Company |
0.52%
|
997,455
|
$32,147,975 | — | 31 Mar 2024 | |
| MORGAN STANLEY |
13F
|
Company |
0.48%
|
927,071
|
$29,879,514 | — | 31 Mar 2024 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.48%
|
923,681
|
$29,770,239 | — | 31 Mar 2024 | |
| Soleus Capital Management, L.P. |
13F
|
Company |
0.38%
|
728,700
|
$23,486,001 | — | 31 Mar 2024 | |
| Finepoint Capital LP |
13F
|
Company |
0.35%
|
677,100
|
$21,822,933 | — | 31 Mar 2024 | |
| Avidity Partners Management LP |
13F
|
Company |
0.33%
|
635,000
|
$20,466,050 | — | 31 Mar 2024 | |
| PERCEPTIVE ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
868,885
mixed-class rows
|
$19,992,289 | — | 31 Mar 2024 | |
| VICTORY CAPITAL MANAGEMENT INC |
13F
|
Company |
0.31%
|
600,581
|
$19,356,726 | — | 31 Mar 2024 | |
| CITADEL ADVISORS LLC |
13F
|
Company |
—
mixed-class rows
|
621,810
mixed-class rows
|
$18,959,472 | — | 31 Mar 2024 | |
| S.c.a. Candriam |
13F
|
Individual |
0.3%
|
583,950
|
$18,820,708 | — | 31 Mar 2024 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.28%
|
544,086
|
$17,535,892 | — | 31 Mar 2024 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.27%
|
529,409
|
$17,062,852 | — | 31 Mar 2024 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.27%
|
511,894
|
$16,498,344 | — | 31 Mar 2024 | |
| MIC Capital Management UK LLP |
13F
|
Company |
0.26%
|
508,569
|
$16,391,179 | — | 31 Mar 2024 | |
| Integral Health Asset Management, LLC |
13F
|
Company |
0.22%
|
420,000
|
$13,536,600 | — | 31 Mar 2024 | |
| Nuveen Asset Management, LLC |
13F
|
Company |
0.19%
|
373,775
|
$12,046,769 | — | 31 Mar 2024 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.19%
|
361,000
|
$11,635,030 | — | 31 Mar 2024 | |
| Mass General Brigham, Inc |
13F
|
Company |
0.18%
|
338,191
|
$10,899,896 | — | 31 Mar 2024 |
Institutional Holders of Revolution Medicines, Inc. - Common Stock (RVMD) as of Q2 2024
As of 30 Jun 2024,
Revolution Medicines, Inc. - Common Stock (RVMD) was held by
221 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
168,410,110 shares.
The largest 10 holders included
VANGUARD GROUP INC, WELLINGTON MANAGEMENT GROUP LLP, BlackRock Inc., FARALLON CAPITAL MANAGEMENT LLC, BAKER BROS. ADVISORS LP, Nextech Invest Ltd., BVF INC/IL, FMR LLC, Alphabet Inc., and Paradigm Biocapital Advisors LP.
This page lists
222
institutional shareholders reporting positions in this security
for the Q2 2024 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q2 2024 vs Q1 2024 Across Filers
Q1 2024 holders
207
Q2 2024 holders
221
Holder diff
14
| Investor | Q1 2024 Shares | Q2 2024 Shares | Share Diff | Share Chg % | Q1 2024 Value $ | Q2 2024 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.